Cell line, viii

Several companies have expressed the cDNA coding for human factor VIII C in a variety of eukaryotic production systems (human VIII C contains 25 potential glycosylation sites). CHO cells and BHK cell lines have been most commonly used, in addition to other cell lines, such as various mouse carcinoma cell lines. The recombinant factor VIII product generally contains only VIII C (i.e. is devoid of vWF). However, both clinical and preclinical studies have shown that administration of this product to patients suffering from haemophilia A is equally as effective as administering blood-derived factor VIII complex. The recombinant VIII C product appears to bind plasma... 

Table VIII. Proliferative response of an SJL T-cell line obtained by 4 passages with free extended site 4...

Recombinate (rhFactor VIII produced in an animal cell line) Baxter Healthcare/ Haemophilia A Genetics Institute 1992 (USA)... 

Clinical trials have demonstrated excellent efficacy with recombinant human factor VIII concentrates available as Recombinate and Kogenate. These recombinant factor VIII products are purified from the cell culture of plasmids, not viral DNA-transfected hamster cells and therefore do not express viral sequences. The addition of human serum albumin for stabilization, constitutes the sole possible source for human viral contamination. More recently recombinant factor IX has been genetically engineered by insertion of the human factor IX gene into a Chinese hamster ovary cell line. It has been proved to be safe and effective in the treatment of patients with hemophilia B. 

Recombinate (rh Factor VIII) Animal cell line Baxter Healthcare/Genetics Institute Hemophilia A... 

Advate (octocog-a, rhFactor VIII produced in CHO cell line the product is similar to Recombinate except it is expressed in culture media free from animal-derived proteins and formulated without plasma-derived human albumin) Baxter hemophilia A 2004 (EU)... 

Sweden factor VIII antihemophilic Recombinate Recombinant human Factor VIII, produced in an animal cell line Hemophilia... 

Advances in recombinant technology alleviated the problem of protein production and its purity. Through the process of recombinant DNA technology and use of nonhuman cell lines, human proteins can be manufactured free of viral contamination. This process enables production of large quantities of proteins previously difficult to obtain from human sources. Further isolation of protein from human sources is associated with a high risk of viral contamination. One such example, plasma derived clotting factor VIII isolated from human blood, resulted in transmission of viral diseases such as hepatitis and AIDS [1,2]. 

The complete 7 kb protein-coding sequence of human factor VIII was assembled from portions of overlapping cDNA and genomic clones and Introduced into appropriate mammalian expression vectors (9,10). Following transformation into either hamster kidney cells (9) or COS-1 monkey cells (11) factor VIII expression in transfected cell lines was characterized. The recombinant protein was shown to be biologically active, demonstrating the ability to activate factor IX and to reduce clotting time in plasma derived from patients affected with hemophilia A. Additionally, factor VIII activity of transfected cells was inhibited by a factor Vlll-specific antibody. 

Fig. VIII-8. Surface structures (a) (1 x 1) structure on the (100) surface of a FCC crystal (from Ref. 76) (b) C(2 x 1) surface structure on the (100) surface of a FCC ciystal (from Ref. 76). In both cases the unit cell is indicated with heavy lines, and the atoms in the second layer with pluses. In (b) the shaded circles mark shifted atoms. (See also Ref. 77.)...

Results of IgM determinations in rabbit antisera to line-1 and line-10 are shown in Table VIII along with the IgG levels obtained by measuring direct binding of [ I]PA to cells treated with unabsorbed antisera. 

---